

**KIMIA BIOSCIENCES LIMITED**

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025**

S. No	Particulars	Quarter ended			Year Ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,358.41	3,824.38	2,239.93	11,892.08
II	Other Income	84.69	44.20	8.33	132.03
III	<b>Total Income (I+II)</b>	<b>2,443.10</b>	<b>3,868.58</b>	<b>2,248.26</b>	<b>12,024.11</b>
IV	<b>Expenses:</b>				
	a) Cost of materials consumed	1,706.19	2,892.82	1,497.22	7,455.02
	b) Change in inventories of finished goods and work-in-prog	(290.32)	(449.82)	(274.57)	(368.23)
	c) Employee benefits expenses	327.67	278.56	342.83	1,367.89
	d) Finance costs	174.71	140.16	110.84	455.70
	e) Depreciation and amortisation expense	93.53	87.90	89.78	337.89
	f) Other expenses	362.18	284.78	303.96	1,412.42
V	<b>Total Expenses (IV)</b>	<b>2,373.96</b>	<b>3,234.40</b>	<b>2,070.06</b>	<b>10,660.69</b>
VI	<b>Profit/(loss) before exceptional items and Tax (III-V)</b>	<b>69.14</b>	<b>634.18</b>	<b>178.20</b>	<b>1,363.42</b>
VII	Exceptional Items	-	-	-	-
VI	<b>Profit/(loss) before tax (IV-V)</b>	<b>69.14</b>	<b>634.18</b>	<b>178.20</b>	<b>1,363.42</b>
VII	<b>Tax expenses:</b>				
	a) Current Tax		-	29.74	-
	b) Deferred Tax charge / (credit)	8.74	435.01	4.75	402.18
VIII	<b>Profit/(loss) for the period (VI-VII)</b>	<b>60.40</b>	<b>199.17</b>	<b>143.70</b>	<b>961.24</b>
IX	<b>Other Comprehensive Income</b>				
A.	Items that will not be reclassified to Profit or Loss (Net of				
	- Remeasurement of defined benefit plans	-	-	-	-
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-
X	<b>Total Comprehensive Income for the period (VIII+IX)</b>	<b>60.40</b>	<b>199.17</b>	<b>143.70</b>	<b>961.24</b>
XI	Paid up equity share capital (Face value of Rs. 1 per equity share)	473.13	473.13	473.13	473.13
XII	<b>Other Equity</b>				<b>523.48</b>
XIII	<b>Earnings per equity share (not annualised)</b>				
	Basic in Rs.	0.13	0.42	0.30	2.03
	Diluted in Rs.	0.13	0.42	0.30	2.03

**Other Notes**

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for three months ended June 30, 2025 are the balancing figure between audited figures in respect of the full financial year and published year to date figures up to the nine months of the previous financial year. The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2025.

Date : August 14, 2025

Place : New Delhi

FOR KIMIA BIOSCIENCES LIMITED



*Sameer Goel*  
Sameer Goel  
(Director)  
DIN - 00161786



Review Report

To  
The Board of Directors  
Kimia Biosciences Limited  
Village Bhondsi, Tehsil Sohna  
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended June 30, 2025 and year to date results for the period from April 01, 2025 to June 30, 2025 (the "Statement"), being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes.
2. The statement is the responsibility of the Company's Management which has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Neeraj Arora and Associates  
FRN 021309

Neeraj Kumar Arora  
M. No. 510750  
UDIN:- 25510750BMIEGQ8394  
Place:- Gurugram  
Dated:- August 14, 2025

